Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis?

The Journal of international medical research - 1 May 2020

Liu Yanquan, Shen Jianzhen, Awal Issah M, Liu Tingbo, Zhou Huarong, Fu Haiying

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is the most common adult non-Hodgkin lymphoma (NHL) and is highly invasive, with a poor prognosis. The main clinical treatment for DLBCL involves chemotherapy or a combination of chemotherapy and targeted drugs. CD56 expression is considered as an indicator of poor prognosis in patients with acute myeloid leukemia and anaplastic large cell lymphoma; however, its role in DLBCL...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Burkitt Lymphoma
Share to CD56 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Doxorubicin

Share to Etoposide

Share to Prednisone

Share to Proto-Oncogene Proteins c-bcl-6

Share to Vincristine

Source

Open in PubMed Open full text

Identifiers

PMID: 32363958
DOI: 10.1177/0300060520918087
PMCID: PMC7218936

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis?PMID 32363958Read ↗

Double-Hit Large B Cell Lymphoma.Semantic proximity Read ↗

[Diffuse large B-cell lymphoma: therapeutic development based on clinical and biological heterogeneity].Semantic proximity Read ↗

Clinical features and immunophenotypes of double-hit diffuse large B-cell lymphomaSemantic proximity Read ↗

High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/RearrangementsSemantic proximity Read ↗

Double-hit primary central nervous system lymphoma with histogenetically proven bone marrow infiltration: A case report and a review of the literatureSemantic proximity Read ↗

Clinical implications of CSF-ctDNA positivity in newly diagnosed diffuse large B cell lymphoma.Semantic proximity Read ↗

Clinicopathological features and prognostic factors of rare primary bone marrow diffuse large B cell lymphomaSemantic proximity Read ↗

Double hit lymphoma: from biology to therapeutic implications.Semantic proximity Read ↗

Double-hit lymphomas: current paradigms and novel treatment approaches.Semantic proximity Read ↗

Targeted sequencing reveals the relationship between mutations and patients' clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma.Semantic proximity Read ↗

Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.Semantic proximity Read ↗

Drug therapy for double-hit lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.